Key result
PPIs are prescribed to only ~23% of aspirin users with CVD and GI risk factors.
Why the study?
What is the prevalence of proton pump inhibitor use among aspirin users with established cardiovascular disease at high risk for upper gastrointestinal complications?
Population
Subjects with established cardiovascular disease, of whom 86% were regular aspirin users.
Design
Cross-sectional
Authors
Loading...
PPI gastroprotection appears underused among high-risk aspirin users; leaves open whether targeted interventions reduce GI complications.
Cross-Sectional
What is the prevalence of proton pump inhibitor use among aspirin users with established cardiovascular disease at high risk for upper gastrointestinal complications?
There is significant underutilization of proton pump inhibitors for gastroprotection among high-risk aspirin users with established cardiovascular disease.
Targownik et al. (2008) conducted a cross-sectional in established cardiovascular disease. Proton pump inhibitors (PPIs) was evaluated on Prevalence of PPI use among aspirin users with risk factors. Among aspirin users with cardiovascular disease, 71% had at least one risk factor for upper gastrointestinal complications, yet only 23% of those with additional risk factors were prescribed a PPI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: